A weekly subcutaneous injection is sufficient to deliver the anti-miR without loss of activity
Common reported side effects: Gastrointestinal effects are the most frequently reported side effects across published GLP-1 clinical trials and FDA labeling, including nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and acid reflux
Report these symptoms to your healthcare provider immediately, and seek emergency care for severe uncontrolled bleeding or signs of stroke
NFLX +1.74%Yesterday, 1:26 PM12 Comments Apple is said to focus on privacy to ease smart glasses concerns AAPL +3.53%Yesterday, 12:57 PM11 Comments Goldman Sachs CEO backs U.S
The doses used in trials were around 500ug/kg, which means a 100kg person was receiving 50mg of the peptide daily. $50 million in research and development down the drain for a promising product that was no longer a viable pharmaceutical product
Hekler, A